Amoy Diagnostics Co., Ltd. (SHE:300685)

China flag China · Delayed Price · Currency is CNY
21.85
-0.16 (-0.73%)
Dec 1, 2025, 3:04 PM CST
-13.53%
Market Cap8.51B
Revenue (ttm)1.13B
Net Income (ttm)290.10M
Shares Out386.86M
EPS (ttm)0.74
PE Ratio29.82
Forward PE25.30
Dividend0.30 (1.36%)
Ex-Dividend DateJun 3, 2025
Volume4,311,216
Average Volume5,824,739
Open22.01
Previous Close22.01
Day's Range21.76 - 22.05
52-Week Range19.27 - 27.17
Beta0.76
RSI40.86
Earnings DateApr 20, 2026

About Amoy Diagnostics

Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a comprehensive genomic profiling assay; AmoyDx BRCA Pro panel,... [Read more]

Sector Healthcare
Founded 2008
Employees 1,144
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300685
Full Company Profile

Financial Performance

In 2024, Amoy Diagnostics's revenue was 1.11 billion, an increase of 6.27% compared to the previous year's 1.04 billion. Earnings were 254.86 million, a decrease of -2.53%.

Financial Statements

News

There is no news available yet.